Loading...

Purified anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
GK1dot5_Pure_021706
BALB/c mouse splenocytes were stained with purified CD4 (clone GK1.5) (filled histogram) or rat IgG2b, κ isotype control (open histogram), followed by anti-rat IgG FITC.
  • GK1dot5_Pure_021706
    BALB/c mouse splenocytes were stained with purified CD4 (clone GK1.5) (filled histogram) or rat IgG2b, κ isotype control (open histogram), followed by anti-rat IgG FITC.
Cat # Size Price Quantity Check Availability Save
100401 50 µg 20€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100402 500 µg 62€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
IHC-F, IP - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Zander R, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.10.077. PubMed
  2. Zhang S, et al. 2017. Nature.. 10.1038/nature24283. PubMed
  3. Ma W, et al. 2017. Sci Rep. . 10.1038/s41598-017-15661-6. PubMed
  4. Biton M et al. 2018. Cell. 175(5):1307-1320 . PubMed
  5. Scutts SR, et al. 2018. Cell Rep. 25:1953. PubMed
  6. Luu M, et al. 2019. Nat Commun. 10:760. PubMed
  7. Gao J, et al. 2017. Oncol Lett. 14:2954. PubMed
  8. Pradhan P, et al. 2017. JCI Insight. 2. PubMed
  9. Pierini A, et al. 2017. JCI Insight. 2. PubMed
  10. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
  11. Di Dalmazi G, et al. 2019. J Immunol. 202:1350. PubMed
  12. Shimokawa C et al. 2017. Immunity. 46(5):863-874 . PubMed
  13. Overacre-Delgoffe AE, et al. 2017. Cell. 169:1130. PubMed
  14. He X, et al. 2017. Cancer Biol Ther. 0.815277778. PubMed
  15. Zhang H, et al. 2017. J Immunol. 198:2133. PubMed
  16. Rieck M, et al. 2017. Eur J Immunol. 47:677. PubMed
  17. Stacey MA, et al. 2017. J Clin Invest. 127:1463. PubMed
  18. Song K, et al. 2017. Oncotarget. 8:38554. PubMed
  19. Xie MM, et al. 2017. Eur J Immunol. 47:1136. PubMed
  20. Floudas A, et al. 2017. J Immunol. 199:707. PubMed
  21. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
  22. Zhou AC, et al. 2017. Front Immunol. 1.136111111. PubMed
  23. Shirakawa K, et al. 2017. PLoS One. 12:e0186303. PubMed
  24. Duncan CG, et al. 2018. G3 (Bethesda). 0.892361111. PubMed
  25. Sprouse ML, et al. 2018. JCI Insight. 3:e97322. PubMed
  26. Hoves S, et al. 2018. J Exp Med. 215:859. PubMed
  27. Yates K, et al. 2018. Proc Natl Acad Sci U S A. 115:2162. PubMed
  28. Burrello C, et al. 2018. Front Med (Lausanne). 5:21. PubMed
  29. Sun H, et al. 2018. J Cell Biol. 217:1453. PubMed
  30. Lee JY, et al. 2018. Front Immunol. 0.678472222. PubMed
  31. Elsayed H, et al. 2018. J Virol. 92:e00428. PubMed
  32. Wilhelmson AS, et al. 2018. Arterioscler Thromb Vasc Biol. 38:1519. PubMed
  33. Liu M, et al. 2018. Diabetologia. 61:2333. PubMed
  34. Zhao L, et al. 2018. Nat Med. 24:1536. PubMed
  35. McLeod RL, et al. 2018. Oncotarget. 9:34459. PubMed
  36. Meyers JL, et al. 2018. PLoS One. 13:e0207007. PubMed
  37. Sharabi A, et al. 2019. JCI Insight. 4:e126294. PubMed
  38. Chen S, et al. 2018. Immunohorizons. 0.345138889. PubMed
  39. Leal AS, et al. 2019. Sci Rep. 5.286111111. PubMed
  40. Rosenbaum M, et al. 2019. Nat Commun. 2.05. PubMed
  41. Gartlan KH, et al. 2019. Blood Adv. 2.110416667. PubMed
  42. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
  43. Thi VAD, et al. 2019. Mol Cells. 42:869. PubMed
  44. Thelin MA, et al. 2017. Diabetes. 66:2220. PubMed
  45. Cole C, et al. 2018. Nucleic Acids Res. 46:e62. PubMed
  46. Krovi SH, et al. 2019. Proc Natl Acad Sci U S A. 116:22252. PubMed
  47. Carpenter SM, et al. 2017. PLoS Pathog. 13:e1006704. PubMed
  48. Niss Arfelt K, et al. 2017. Blood. 129:866. PubMed
  49. Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed
  50. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  51. Chen X, et al. 2019. Methods Mol Biol. 2048:131. PubMed
  52. Englezou PC, et al. 2018. Mol Ther Nucleic Acids. 12:118. PubMed
  53. Zhang J, et al. 2019. Onco Targets Ther. 12:4985. PubMed
  54. Shao Y, et al. 2017. Onco Targets Ther. 10:2675. PubMed
  55. Mazor R, et al. 2018. Proc Natl Acad Sci U S A. 115:E733. PubMed
  56. Yang SH, et al. 2017. Front Immunol. 8:1192. PubMed
  57. Seelige R, et al. 2018. Sci Rep. 8:13670. PubMed
  58. Tan L, et al. 2017. Int J Nanomedicine. 12:3095. PubMed
  59. Krämer TJ, et al. 2019. J Neuroinflammation. 16:163. PubMed
  60. Chami B, et al. 2017. Sci Rep. 7:10181. PubMed
  61. Smith CJ, et al. 2018. J Immunol. 200:1580. PubMed
  62. Duvvuri M, et al. 2019. Biomater Sci. 7:1863. PubMed
  63. Skeate JG, et al. 2018. PLoS One. 13:e0191311. PubMed
  64. Stefanski HE, et al. 2018. PLoS One. 13:e0198871. PubMed
  65. Rosenberg J, et al. 2020. Cell Systems. 10(5):433-444. PubMed
  66. Majer O, et al. 2019. Nature. 575:366. PubMed
  67. Matsuo K, et al. 2018. J Invest Dermatol. 138:1764. PubMed
  68. Tsukumo S, et al. 2006. J Immunol. 177:8365. PubMed
  69. Hu M, et al. 2008. J Immunol. 180:6593. PubMed
  70. Fujimura N, et al. 2016. J Vasc Surg. 64: 46-54. PubMed
  71. Kinosada H, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006120. PubMed
  72. Zareie P, et al. 2017. J Neuroinflammation. 0.630555556. PubMed
  73. Zhang Z, et al. 2020. Front Immunol. 1.844444444. PubMed
  74. Hummel JF, et al. 2020. Mucosal Immunol. 0.720138889. PubMed
  75. Goh W, et al. 2020. Cell Rep. 33:108285. PubMed
  76. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  77. Schafflick D, et al. 2020. Nat Commun. 247:11. PubMed
  78. Zelazowska MA, et al. 2020. Life Sci Alliance. :3. PubMed
  79. Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed
  80. Wabitsch S, et al. 2021. STAR Protoc. 2:100517. PubMed
  81. Wang N, et al. 2021. Mol Ther Oncolytics. 20:71. PubMed
  82. Zhang N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  83. Rossi DC, et al. 2021. J Clin Invest. 131:. PubMed
  84. Chen HW, et al. 2021. Biomedicines. 9:. PubMed
  85. Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed
  86. Ikezoe T, et al. 2021. Biomolecules. 11:. PubMed
  87. Horiuchi S, et al. 2021. Sci Immunol. :eabm3131. PubMed
  88. Sharma M, et al. 2020. Nat Commun. 11:661. PubMed
  89. Xie D, et al. 2020. Eur J Immunol. 50:1729. PubMed
  90. Sutiwisesak R, et al. 2020. PLoS Pathog. 16:e1009000. PubMed
  91. Draganov D, et al. 2021. NPJ Breast Cancer. 7:22. PubMed
  92. Wan Mohd Zawawi WFA, et al. 2021. Sci Rep. 11:10278. PubMed
  93. Hirano J, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  94. Kobayashi A, et al. 2021. Front Immunol. 12:650856. PubMed
  95. Lasrado N, et al. 2021. Microorganisms. 9:. PubMed
  96. Liao X, et al. 2022. Front Immunol. 12:768813. PubMed
  97. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  98. Prabakaran T, et al. 2021. EBioMedicine. 66:103314. PubMed
  99. Scortegagna M, et al. 2020. Nat Commun. 11:99. PubMed
  100. Dey P, et al. 2020. Cancer Discov. 10:608. PubMed
  101. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
  102. Paterson MJ, et al. 2020. PLoS Pathog. 16:e1008733. PubMed
  103. Yang J, et al. 2020. Front Immunol. 10:3048. PubMed
  104. Whittle JR, et al. 2020. Clin Cancer Res. 26:4120. PubMed
  105. Murata A, et al. 2020. Front Immunol. 11:775. PubMed
  106. Lin Z, et al. 2021. Stem Cells. 39:240. PubMed
  107. Bajaña S, et al. 2021. Front Immunol. 11:577718. PubMed
  108. Mohrin M, et al. 2021. Aging Cell. 20:e13313. PubMed
  109. Tian K, et al. 2021. J Immunol Res. 2021:6297332. PubMed
  110. Prado C, et al. 2021. J Neuroinflammation. 18:292. PubMed
  111. Fernandes V, et al. 2020. PLoS Pathog. 16:e1008464. PubMed
  112. Mayer JU, et al. 2020. Front Immunol. 11:592325. PubMed
  113. Kästele V, et al. 2021. Mucosal Immunol. 14:717. PubMed
  114. Brownlie D, et al. 2021. J Immunother Cancer. 9:. PubMed
  115. Mayer KA, et al. 2021. FASEB J. 35:e21217. PubMed
  116. Tao H, et al. 2021. Front Immunol. 12:623280. PubMed
  117. Landuyt AE, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  118. Shokirova H, et al. 2021. Sci Rep. 11:8647. PubMed
  119. Haque M, et al. 2021. Viruses. 13:. PubMed
  120. Hashimoto K, et al. 2021. J Dermatol Sci. 102:177. PubMed
  121. Jackson JW, et al. 2021. Mol Ther Oncolytics. 22:444. PubMed
  122. Hsiao CC, et al. 2021. Cells. 10:. PubMed
  123. Tsai MS, et al. 2021. Int J Mol Sci. 22:. PubMed
  124. Stefanescu C, et al. 2021. Front Oncol. 11:765151. PubMed
  125. Mostafavi H, et al. 2022. PLoS Pathog. 18:e1010185. PubMed
  126. Liu H, et al. 2022. Animal Model Exp Med. 5:72. PubMed
  127. Liu J, et al. 2022. Stem Cell Res Ther. 13:247. PubMed
  128. Liu CJ, et al. 2020. Neuro Oncol. 22:1276. PubMed
  129. Yu H, et al. 2020. Front Immunol. 11:1773. PubMed
  130. Malinczak CA, et al. 2021. J Immunol. 206:1315. PubMed
  131. Ngwenyama N, et al. 2022. Nat Cardiovasc Res. 1:761. PubMed
  132. Zhang YN, et al. 2023. Nat Commun. 14:1985. PubMed
RRID
AB_312686 (BioLegend Cat. No. 100401)
AB_312687 (BioLegend Cat. No. 100402)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 1    Revision Date: 11.30.2012

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account